Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.40M | $4.11M | $4.74M | $10.7M | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.65M |
| Revenue growth | — | -6.7% | 15.4% | 125.3% | 194.3% | 77.7% | 72.4% | -34.0% | -78.5% | -51.2% |
| Operating income | -$32.0M | -$42.1M | -$67.1M | -$101M | -$128M | -$217M | -$308M | -$191M | -$210M | -$148M |
| Operating margin | -726.1% | -1025.9% | -1415.4% | -943.1% | -407.5% | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| Net income | -$33.5M | -$43.0M | -$66.6M | -$98.1M | -$173M | -$212M | -$282M | -$161M | -$186M | -$136M |
| Net margin | -760.2% | -1046.1% | -1405.0% | -919.0% | -551.6% | -379.9% | -292.5% | -253.3% | -1366.5% | -2051.1% |
| EPS (diluted) | -$1.05 | -$1.02 | -$1.19 | -$1.44 | -$2.10 | -$2.24 | -$2.91 | -$1.64 | -$1.64 | -$1.15 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$36.8M | -$38.6M | -$83.2M | -$39.2M | -$163M | -$248M | -$132M | -$123M | -$106M |
| Capital expenditures | $457K | $1.73M | $2.30M | $7.39M | $4.93M | $50.7M | $35.6M | $6.15M | $730K | $5.95M |
| Free cash flow | -$30.3M | -$38.5M | -$41.0M | -$90.6M | -$44.2M | -$214M | -$284M | -$138M | -$124M | -$112M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $88.6M | $89.0M | $191M | $99.8M | $167M | $134M | $61.3M | $41.9M | $36.1M | $46.6M |
| Total assets | $95.0M | $105M | $213M | $302M | $622M | $921M | $706M | $506M | $441M | $319M |
| Long-term debt | $2.50M | $14.8M | $12.4M | — | — | — | — | — | — | — |
| Shareholders' equity | $73.2M | $77.2M | $160M | $245M | $384M | $679M | $484M | $368M | $319M | $207M |
| Retained earnings | -$176M | -$219M | -$285M | -$384M | -$557M | -$769M | -$1.05B | -$1.21B | -$1.40B | -$1.53B |
| Shares (wtd avg diluted) | 41.4M | 52.6M | 64.7M | 75.7M | 82.4M | 94.7M | 96.8M | 98.4M | 114M | 119M |
Every figure is extracted from FATE THERAPEUTICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.